How many insider trades does FilingIQ track for JBIO?

FilingIQ tracks 17 Form 4 insider transactions for JBIO (Jade Biosciences, Inc.), covering filings from Apr 28, 2025 onwards. 5 of those were filed in the last 90 days.

Are JBIO insiders net buyers or net sellers?

Across the full Form 4 history for JBIO, 1 transactions (6%) were open-market purchases and 0 (0%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.

Where does JBIO insider data come from?

Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.

What sector is JBIO in?

Jade Biosciences, Inc. (JBIO) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $696.32M.

JBIO insider trading

Healthcare

Jade Biosciences, Inc. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.

Total Form 4 trades

Last 90 days

Buys / sells

6% / 0%

Market cap

$696.32M

About Jade Biosciences, Inc.

Jade Biosciences, Inc. operates as a biotechnology company that develops therapies for inflammation and immunology indications in patients living with autoimmune diseases. The company develops JADE101, a monoclonal antibody to block the A PRoliferation Inducing Ligand protein, which is in phase 1 clinical trial. It also develops JADE201 and JADE-003, which are in preclinical development stage. Jade Biosciences, Inc. has a collaboration agreement with Paragon Therapeutics, Inc. Jade Biosciences, Inc. is based in Waltham, Massachusetts.

Company website: jadebiosciences.com

JBIO insider activity at a glance

FilingIQ has scored 17 insider transactions for JBIO since Apr 28, 2025. The most recent filing in our index is dated Jun 9, 2026.

Across the full history, 1 open-market purchases and 0 open-market sales were filed under transaction codes P and S respectively. Compensatory share awards (code A) and option exercises (code M) are tracked separately and not counted here.

The average FilingIQ composite score on JBIO insider trades is 62.0/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.

View live JBIO trades on FilingIQ Raw filings on SEC EDGAR

Other Healthcare tickers with recent insider activity

UTHR 1,223

UNITED THERAPEUTICS Corp

APLS 275

Apellis Pharmaceuticals, Inc.

KMDA 218

KAMADA LTD

GH 152

Guardant Health, Inc.

KalVista Pharmaceuticals, Inc.

KNSA 129

Kiniksa Pharmaceuticals International, plc

13F funds holding JBIO

Opaleye Management Inc.

$6.60M · 0.9% of AUM

Frequently asked

How many insider trades does FilingIQ track for JBIO?: FilingIQ tracks 17 Form 4 insider transactions for JBIO (Jade Biosciences, Inc.), covering filings from Apr 28, 2025 onwards. 5 of those were filed in the last 90 days.
Are JBIO insiders net buyers or net sellers?: Across the full Form 4 history for JBIO, 1 transactions (6%) were open-market purchases and 0 (0%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
Where does JBIO insider data come from?: Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
What sector is JBIO in?: Jade Biosciences, Inc. (JBIO) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $696.32M.

Methodology & sources

Every JBIO insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.